Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sumitomo Dainippon’s Sales Down 1.6% on Price Cuts, Generic Erosions
Sumitomo Dainippon Pharma saw its group revenue inch down 1.6% to 459,267 million yen in the year ended March 2019 as drug price cuts and generic encroachments dealt a blow to its Japan business, according to its earnings released on…
To read the full story
Related Article
- Sumitomo Dainippon Ekes Out Quarterly Growth as North America Sales Offset Japan Dip
July 30, 2019
- Sunovion to Push Different Dasotraline Trial Data in FDA Negotiations: Sumitomo Dainippon Chief
May 13, 2019
- Sumitomo Dainippon Cuts Sales Outlook for FY2018, Ups Profit Forecast
April 22, 2019
- Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions
October 31, 2018
- Sumitomo Dainippon’s Sales Hike 14.3% Buoyed by Latuda
May 14, 2018
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…